The EU Clinical Trials Regulation (EU CTR 536/2014) established a unified framework for the submission, assessment, and supervision of clinical trials across the European Union. At its core lies the Clinical Trials Information System (CTIS) — a single portal that centralizes communication between sponsors, Competent Authorities, and Ethics Committees.
Pharmaxi provides complete end-to-end support for CTA submissions via CTIS, ensuring your clinical trial application meets all regulatory and technical requirements. Our regulatory experts guide sponsors through every step — from dossier compilation to post-approval lifecycle management — ensuring smooth, compliant submissions under the EU CTR framework.
The Clinical Trials Regulation replaced the previous Clinical Trials Directive to simplify multi-country submissions and increase transparency. CTIS enables sponsors to submit one harmonized Clinical Trial Application (CTA) valid across all EU and EEA member states. This unified approach significantly reduces administrative burden and accelerates approvals.
However, CTIS introduces new challenges — a complex interface, strict submission requirements, and defined response timelines for authorities’ requests. Expert handling of the submission process ensures compliance and prevents costly delays or rejections.
A successful CTA submission via CTIS requires thorough preparation, regulatory precision, and coordinated communication. Pharmaxi manages the process step by step:
Our experience allows sponsors to focus on study execution while Pharmaxi ensures compliance and transparency throughout the process.
Under the EU CTR, a Substantial Modification (SM) refers to any significant change that may impact participant safety, scientific value, or study conduct — for example, protocol amendments, investigator changes, or updates to IMP composition.
Pharmaxi helps sponsors assess whether a proposed change qualifies as a substantial modification and prepares the required documentation for submission through CTIS. We handle all interactions with regulators to ensure modifications are processed efficiently and without study disruption.
Pharmaxi combines deep regulatory expertise with hands-on experience in CTIS operations since its implementation. Our dedicated regulatory team has managed single-country and multi-country CTA submissions across multiple EU markets, supporting both commercial and non-commercial sponsors.
We ensure that all documents are correctly formatted, uploaded, and validated within the system — minimizing errors and ensuring fast review cycles. From Part I and II documentation preparation to post-submission follow-up, Pharmaxi takes control of the entire submission process.
If you are preparing a CTA submission under the EU CTR, Pharmaxi can guide you through the process from start to finish.
We manage documentation, system validation, and regulatory communication — ensuring your study launches on time and in full compliance with EU requirements.
👉 Contact us today to learn more about our CTIS submission services and start your clinical trial journey with confidence.
